Largest Healthcare Data Breaches Still Matter Years Later, With 2024 Exposing Over 276 Million Records TechNadu
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
